Ipsen to Buy Kartos Therapeutics for Up to $1.75 Billion

French biopharma Ipsen has agreed to acquire Kartos Therapeutics in a deal valued at up to **$1.75 billion**, though initial coverage notes a **$450 million upfront payment** with potential additional payments tied to milestones. Kartos’s lead asset—a late-stage therapy for myelofibrosis—is central to the acquisition, with Fierce Biotech specifying its potential as an **add-on to Incyte’s Jakafi**. The move expands Ipsen’s hemato-oncology pipeline, a focus area for the company’s growth strategy.

Coverage highlights discrepancies in deal valuation: Reuters and Endpoints News report a **$450 million upfront** figure, while Ipsen’s own statement and WSJ frame the total potential at **$1.75 billion**. FirstWord Pharma and GlobeNewswire emphasize the **late-stage pipeline expansion** and Kartos’s blood cancer asset as key drivers. Fierce Biotech ties the acquisition to a **specific therapeutic target (myelofibrosis)**, underscoring its strategic fit for Ipsen’s existing portfolio.

Watch for clarification on the **deal’s milestone structure**—whether the $1.75B cap includes equity, earn-outs, or other contingent payments. Ipsen’s integration plans for Kartos’s pipeline, particularly the myelofibrosis program, will draw scrutiny, as will potential regulatory hurdles for the asset’s approval. Incyte’s Jakafi partnership may also face scrutiny over competitive dynamics in the myelofibrosis space.